Loading...
•
Sep 30, 2021
Evofem Biosciences Q3 2021 Earnings Report
Reported financial results for Q3 2021 and provided a corporate update.
Key Takeaways
Evofem Biosciences reported Phexxi net product sales of $1.7 million for the third quarter of 2021. The company experienced a 29% increase in gross revenues compared to the second quarter of 2021, driven by ex-factory sales growth. Operating expenses increased by 5% to $45.1 million. The company expects to reduce operating expenses by approximately $50 million in 2022.
Over 19,000 Phexxi TRx in Q3 2021, a 48% increase over Q2 2021.
10,700 Phexxi NRx and over 13,600 TRx in the six weeks following the celebrity DTC campaign launch, up 94% and 81%, respectively, vs. preceding six-week period.
More than 10,000 healthcare providers have prescribed Phexxi since launch.
Company expects to reduce operating expenses by approximately $50 million in 2022.
Evofem Biosciences
Evofem Biosciences
Evofem Biosciences Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.com Forward Guidance
The company expects to reduce operating expenses by approximately $50 million in 2022.